GEMINA LABS PRESENTS AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

September 12, 2022

GEMINA LABORATORIES LTD. 

News Release 

September 12, 2022 

GEMINA LABS PRESENTS AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE 

September 12, 2022, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7)  (US: OTC GLABF) (the “Company” or “Gemina”) is pleased to announce its participation both virtually  and in person at the H.C. Wainwright 24th Annual Global Investment Conference. Gemina’s presentation hosted by CEO Brian Firth, will be available for viewing on Monday September 12, 2022,  beginning at 7:00 a.m. EST. Mr. Firth will also be attending the live event and available for one on one  meetings. 

The on-demand webcast of the presentation may be accessed through the following link: Gemina Labs - HC Wainwright Presentation. A replay of the webcast will be available through this link for 30 days. 

On Behalf of the Board of Directors, 

Brian Firth 

CEO 

Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect  human health and wellness. Our technology drives testing platforms that are fast, affordable and  accurate, and easily self-administered. Our development pipeline includes platforms for the rapid  testing of COVID-19, influenza and other viruses. Additional information on the Company can be found  at www.geminalabs.com. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is  defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy  or accuracy of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are  not limited to, information and statements regarding or inferring the future business, operations,  financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of  the Company. Such statements include statements regarding the anticipated terms of any proposed  transaction or engagement. Information and statements which are not purely historical fact are  forward-looking statements. Forward-looking information and statements involve and are subject to  assumptions and known and unknown risks, uncertainties, and other factors which may cause actual  events, results, performance, or achievements of the Company to be materially different from future  events, results, performance, and achievements expressed or implied by forward-looking information  and statements herein. Although the Company believes that any forward-looking information and  statements herein are reasonable, in light of the use of assumptions and the significant risks and  uncertainties inherent in such information and statements, there can be no assurance that any such 

forward-looking information and statements will prove to be accurate, and accordingly readers are  advised to rely on their own evaluation of such risks and uncertainties and should not place undue  reliance upon such forward-looking information and statements. Furthermore, the Company is  presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations  and recognizes that certain eventualities may affect planned or assumed performance moving  forward. As such, any forward-looking information and statements herein are made as of the date  hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims  any intention to update or revise any forward-looking information and statements herein or to update  the reasons that actual events or results could or do differ from those projected in any forward looking  information and statements herein, whether as a result of new information, future events or results,  or otherwise, except as required by applicable laws.  

For more information regarding the Company, please contact: 

Brian Firth 

Telephone: +44 7568 539192 

Email: bfirth@geminalabs.com 

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

AGM DOCUMENTATION

December 20, 2022
Read More

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022
Read More

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.